J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
Express News | Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 From $8
Kyverna Therapeutics GAAP EPS of -$0.67
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
Kyverna Therapeutics Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Autoimmune Disorder Drug
Express News | Kyverna Therapeutics Inc - Qtrly Shr Loss $0.67
Express News | Kyverna Therapeutics Q2 EPS $(0.67) Misses $(0.64) Estimate
Kyverna Therapeutics | 10-Q: Quarterly report
Express News | Kyverna Therapeutics Receives U.S. FDA RMAT Designation For KYV-101 In Treatment Of Progressive Myasthenia Gravis
Express News | Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Express News | Kyverna Therapeutics Receives U.S. FDA Rmat Designation for Kyv-101 in the Treatment of Patients With Progressive Myasthenia Gravis
We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth
Express News | JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $33
Express News | Kyverna Therapeutics Inc : JP Morgan Cuts Target Price to $33 From $39
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40